Squamous Cell Carcinoma (SCC) Cell Models for Research

Squamous cell carcinoma (SCC) arises from squamous epithelial cells and accounts for a substantial proportion of cancers of the skin, head and neck, lung, esophagus, cervix, and anus. According to the World Health Organization (WHO), cancers of the skin (non-melanoma) are among the most common malignancies globally, with SCC being the second most frequent type. For head and neck squamous cell carcinoma (HNSCC), the Global Cancer Observatory (GLOBOCAN) 2020 data reported approximately 930,000 new cases and 470,000 deaths annually. The National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results (SEER) database indicates that the 5-year relative survival for localized HNSCC is about 84%, but drops to 65% for regional spread and 39% for distant metastasis. Cutaneous SCC has a generally favorable prognosis, but metastatic disease carries a 5-year survival of less than 20%. Major risk factors include tobacco use, alcohol consumption, human papillomavirus (HPV) infection (for oropharyngeal and cervical SCC), ultraviolet radiation exposure (for skin SCC), and immunosuppression. The high recurrence rates and resistance to conventional therapies in advanced stages underscore the urgent need for better preclinical models.

SCC is an ideal model for studying epithelial carcinogenesis due to its well-defined progression from premalignant lesions (e.g., actinic keratosis, leukoplakia) to invasive carcinoma. The availability of large public datasets, such as The Cancer Genome Atlas (TCGA) for HNSCC and lung SCC, provides comprehensive genomic, transcriptomic, and epigenetic profiles. Key open questions include the role of tumor heterogeneity, the interplay between genetic alterations and the tumor microenvironment, and mechanisms of resistance to immune checkpoint inhibitors. Gene-edited cell models that recapitulate specific mutations allow researchers to dissect causal relationships in these processes.

Several core pathways are frequently deregulated in SCC:

• • Cell cycle regulation: Loss of TP53 and CDKN2A leads to uncontrolled G1/S transition.
• • Growth factor signaling: Activation of EGFR, ERBB2, and MET promotes proliferation and survival.
• • Differentiation and apoptosis: NOTCH1 mutations impair squamous differentiation and promote apoptosis resistance.
• • Oxidative stress response: NFE2L2 (NRF2) mutations confer resistance to oxidative damage.
• • Epigenetic remodeling: Mutations in KMT2D, KMT2C, and CREBBP alter histone methylation and acetylation.

Data from TCGA (HNSCC, lung SCC) and COSMIC (Catalogue of Somatic Mutations in Cancer) reveal recurrent alterations:

These frequencies vary by anatomical site and HPV status.

Key signaling networks in SCC include:

• • EGFR/MAPK pathway: EGFR overexpression or mutation activates RAS-RAF-MEK-ERK cascade, driving proliferation.
• • PI3K/AKT/mTOR pathway: PIK3CA mutations or PTEN loss lead to survival and metabolic reprogramming.
• • Wnt/β-catenin pathway: Aberrant activation promotes stemness and invasion.
• • JAK/STAT pathway: Cytokine signaling supports inflammation and immune evasion.
• • Hippo pathway: YAP/TAZ activation contributes to tissue overgrowth.
• • NOTCH signaling: Loss-of-function mutations disrupt squamous differentiation.

Common SCC cell lines and their key mutations (based on NCBI Gene, COSMIC, and DepMap):

Organoid cultures derived from patient tumors preserve 3D architecture and cellular heterogeneity, making them valuable for drug testing and personalized medicine approaches. However, they are more complex to maintain and less amenable to high-throughput genetic manipulation compared to 2D cell lines.

Animal models for SCC include:

• • Patient-derived xenografts (PDX): Implantation of human tumor tissue into immunodeficient mice; retains tumor heterogeneity but lacks immune system.
• • Genetically engineered mouse models (GEMM): Conditional knockout of TP53 and CDKN2A in squamous epithelium (e.g., K14-Cre; Tp53fl/fl; Cdkn2afl/fl) recapitulates HNSCC.
• • Chemical carcinogenesis models: Application of DMBA/TPA on mouse skin induces cutaneous SCC.
• • HPV-driven models: Expression of HPV16 E6/E7 in oral epithelium leads to SCC.
• • Orthotopic models: Injection of SCC cells into the tongue or skin to mimic local invasion.

CRISPR-based gene editing enables the creation of isogenic cell lines with precise genetic modifications, such as knockout (KO), knock-in (KI), point mutations, and reporter tags. These models are essential for studying the functional impact of specific mutations in a controlled genetic background. Examples include:

• • TP53 knockout in SCC-25 or CAL-27 to study loss-of-function effects.
• • KRAS G12D knock-in in lung SCC cell lines to model oncogenic activation.
• • NOTCH1 knockout to investigate differentiation defects.
• • GFP or luciferase reporter lines for in vivo imaging.

Commercially available, sequence-verified gene-edited cell lines (from sources such as those offering CRISPR services) accelerate research by providing validated tools, reducing experimental variability, and enabling reproducible results. These models are used for target validation, drug screening, and mechanistic studies.

Gene-edited cells allow systematic evaluation of gene function. For example:

• • TP53 knockout in SCC lines confirms its role in apoptosis and cell cycle arrest.
• • CDKN2A knockout leads to increased proliferation and colony formation.
• • NOTCH1 knockout results in loss of differentiation markers (e.g., involucrin, keratins).
• • PIK3CA H1047R knock-in activates AKT signaling and enhances migration.

These models enable CRISPR-based synthetic lethality screens to identify vulnerabilities in specific genetic backgrounds.

Isogenic pairs (wild-type vs. mutant) are used in high-throughput drug screens to identify compounds that selectively kill mutant cells. For example:

• • TP53-null cells are more sensitive to DNA-damaging agents but resistant to p53-dependent apoptosis.
• • EGFR-mutant or overexpressing cells respond to EGFR inhibitors (e.g., cetuximab, erlotinib).
• • PIK3CA-mutant cells show sensitivity to PI3K inhibitors (e.g., alpelisib).

Resistance models can be generated by chronic exposure to drugs, followed by CRISPR editing to pinpoint resistance mutations.

CRISPR screens using gene-edited cell lines help identify biomarkers for patient stratification. For example:

• • Synthetic lethality screens reveal genes that are essential only in TP53-mutant cells, such as G2M checkpoint kinases (e.g., WEE1).
• • Reporter lines (e.g., PD-L1 promoter reporters) enable high-throughput screening for immune evasion modulators.
• • Knockout of candidate genes followed by transcriptomic analysis identifies downstream biomarkers.